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ABSTRACT
Objective: The aim of this study was to compare the predictive validity
of eight different adherence measures by studying the variability ex-
plained between each measure and hospitalization episodes among
Medicaid-eligible persons diagnosed with schizophrenia on antipsychotic
monotherapy.
Methods: This study was a retrospective analysis of the Arkansas Med-
icaid administrative claims data. Continuously eligible adult schizophrenia
(ICD-9-CM = 295.**) patients on antipsychotic monotherapy were iden-
tiﬁed in the recruitment period from July 2000 through April 2004.
Adherence rates to antipsychotic therapy in year 1 were calculated using
eight different measures identiﬁed from the literature. Univariate and
multivariable logistic regression models were used to prospectively predict
all-cause and mental health-related hospitalizations in the follow-up year.
Results: Adherence rates were computed for 3395 schizophrenic patients
with a mean age of 42.9 years, of which 52.5% (n = 1782) were females,
and 52.8% (n = 1793) were white. The proportion of days covered
(PDC) and continuous measure of medication gaps measures of adher-
ence had equal C-statistics of 0.571 in predicting both all-cause and
mental health-related hospitalizations. The medication possession ratio
(MPR) continuous multiple interval measure of oversupply were the
second best measures with equal C-statistics of 0.568 and 0.567 for
any-cause and mental health-related hospitalizations. The multivariate
adjusted models had higher C-statistics but provided the same rank order
results.
Conclusions: MPR and PDC were among the best predictors of
any-cause and mental health-related hospitalization, and are recom-
mended as the preferred adherence measures when a single measure
is sought for use with administrative claims data for patients not on
polypharmacy.
Keywords: adherence, pharmacy claims, schizophrenia, validation.
Introduction
The International Society for Pharmacoeconomics and Outcomes
Research Medication Compliance and Persistence Work Group
deﬁnes medication adherence as “the extent to which a patient
acts in accordance with the prescribed interval and dose of a
dosing regimen” [1]. Medication nonadherence is commonly
associated with adverse health conditions and increased eco-
nomic burden to the health-care system [2–6], and is a critical
issue especially in case of chronic therapies such as schizophre-
nia. Adherence measures include direct and indirect techniques.
Direct methods include biological assays, whereas indirect
methods consist of pill counts, electronic monitors, and use of
administrative database claims [7]. Indirect methods and, in
particular, use of administrative data are becoming increasingly
popular because they afford ease of use and are considered eco-
nomical; however, there are no clear standards for measuring or
calculating adherence with these indirect approaches.
Medication nonadherence rates in patients suffering from
schizophrenia range from 20% to 89% based on the adherence
deﬁnition used [8]. Adherence measures using pharmacy claims
data have been used to predict health-care cost and utilization
[9–11]. Svarstad et al. found that persons with schizophrenia
with poorer adherence had higher hospitalization rates than their
more adherent counterparts. Additional studies have reported
similar ﬁndings in persons with schizophrenia [5,6]. Non-
adherence to the prescribed treatment may account for 40% of
the rehospitalizations associated with schizophrenia [8]. Thieda
et al. conducted a literature review for the years 1995 through
2002 evaluating the relationship between compliance and the
economic costs of schizophrenia [4]. The authors concluded that
lower compliance was associated with adverse outcomes such as
increased relapse rates with associated costs ranging from
$10,000 to $26,000. Bearing in mind the economic outcomes
associated with medication nonadherence, schizophrenia serves
as a favorable condition to determine the predictive validity of
various adherence measures.
Because of their usefulness in recent years, administrative
claims data have been one of the most commonly used sources
for calculating medication adherence. Medication adherence
measured using pharmacy claims has been validated using other
adherence measures such as patient reports, pill counts, question-
naires, and interviews [12–17]. Despite these validation studies,
there are no standards for the mathematical calculation of adher-
ence using claims data. A systematic review by Andrade et al.
[18] identiﬁed 136 studies that employed administrative claims
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to calculate medication adherence and persistence. About 57%
of the studies considered medication possession ratio (MPR) and
related measures,10% used medication gaps, and 43% used
switching and discontinuation in calculating medication adher-
ence and persistence. Even among the 57% that considered MPR
and related measures, the follow-up period deﬁnitions varied,
ranging from a speciﬁed follow-up period (e.g., 1 year) to the
period between the ﬁrst and last reﬁll. This study emphasized the
lack of consensus among deﬁnitions and methods used to calcu-
late adherence using administrative claims. Hess et al. published
a study that identiﬁed 11 different adherence measures calculated
using administrative claims data, and initiated the idea of stan-
dardizing adherence measures [19]. This study, however, did not
empirically validate these measures.
The primary aim of this study was to prospectively validate
administrative claims-based adherence measures using hospital-
ization as the end point for persons with schizophrenia. Medi-
cation adherence was measured in terms of adherence to
monotherapy within a class of drugs prescribed for treating
schizophrenia. This study sought to identify adherence measures
which had the best predictive validity, in an effort to offer prac-
titioners and researchers an empirical basis for selecting an
adherence measure among eight unique measures based on
administrative claims data.
Methods
To assess the predictive validity of each adherence measure, the
adherence rates among schizophrenia patients were compared
with hospitalization rates. Our primary hypothesis is that an
increase in adherence will be associated with lower hospitaliza-
tion rates. This was a prospective study where adherence was
assessed in year 1 following an index prescription, and hospital-
ization rates were determined in the subsequent year.
The study used patient-linked administrative claims data for
the Arkansas Medicaid population representing adjudicated paid
claims for services rendered from January 1, 2000 through April
30, 2005. A schematic representation of the study periods is
shown in Figure 1. Patients with schizophrenia were identiﬁed
using the ICD-9-CM code of 295.xx (recorded in the medical and
inpatient claims ﬁle) during the “enrollment period” July 1, 2000
through April 30, 2004. An “index date” deﬁned as the date on
which the ﬁrst prescription for oral antipsychotic medication
(conventional: ﬂuphenazine, haloperidol, loxapine, pimozide,
perphenazine, triﬂuoperazine, chlorpromazine, thioridazine,
molindone, thiothixene; atypical: risperidone, quetiapine, olan-
zapine, aripiprazole, clozapine, ziprasidone) was ﬁlled by the
patient in the enrollment period. Adherence rates, deﬁned below,
were computed using eight different adherence deﬁnitions for the
1-year period starting from the index date.
Subjects
The following inclusion and exclusion criteria were used to select
study subjects:
1. Primary diagnosis for schizophrenia (ICD-9-CM = 295.**)
[6,20] recorded in the medical and inpatient claims ﬁle
during the period July 1, 2000 through April 30, 2004
(starting cohort size N = 11,587);
2. Patients with at least one prescription for oral antipsychotic
medication in a 1-year period between July 1, 2000 and
April 30, 2004 (N = 9025; patients excluded N = 2562);
3. Excluded patients less than 18 years of age at the index date
and Qualiﬁed Medicare Beneﬁciaries (N = 7552; patients
excluded N = 1473);
4. Continuous eligibility for the 6 months before and 24
months after the index date (N = 6344; patients excluded
N = 1208);
5. At least two paid claims for an oral antipsychotic medication
in a 1-year period during the period July 1, 2000 through
April 30, 2004 (N = 5936; patients excluded N = 408);
6. Excluding patients taking two different oral antipsychotic
medications simultaneously (N = 3971; patients excluded
N = 1965);
7. Patients were required to have at least one inpatient, out-
patient, pharmacy, or nursing home claim during the post-
index period. This inclusion criterion was imposed to verify
that patients were utilizing Medicaid beneﬁts in the post-
index period (N = 3957; patients excluded N = 14);
8. Excluding patients with a nursing home claim during the
index period (ﬁnal cohort size N = 3395; patients
excluded = 562).
This study was approved by the Institutional Review Board at
the University of Arkansas for Medical Sciences.
Variables
Measures of Medication Adherence
Medication adherence was measured in terms of adherence to
monotherapy within a class of drugs prescribed for treating
Enrollment Period: July 2000 - April 2004 Index Period*     Post Index Period*
2000 2001 2002 2003 2004 365 days 365 days 
Pre-Index
180 Days 
Index Rx 
*Study Period Definitions: 
Pre-Index Period: 180 days before Index date 
Index Date: first antipsychotic Rx in the enrollment period 
Index Period: Index Date + 364 days 
Post Index Period: 365 days after Index Period 
Example: 
Index antipsychotic Rx date: April 30, 2004  
Pre-index period: November 1, 2003 - April 29, 2004 
Index period: April 30, 2004 - April 29, 2005 and  
Post index period: April 30, 2005 - April 29, 2006 
Figure 1 Description of study periods for a person diagnosed with schizophrenia.
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schizophrenia. Patients on two different strengths of the same
drug were included in the study. Second, we allowed for non-
overlapping switching based on a rationale that the patient
should be on some drug that controls schizophrenia. Thus, by
excluding patients on multiple antipsychotic drugs, we reduced
the complexity of adherence calculations.
The 11 adherence measures that were the initial bases of
adherence measures are reported in Table 1 [19]. Three of these
measures—MPR, medication reﬁll adherence, and continuous
measure of medication acquisition (CMA)—have mathematically
equivalent formulas, and only MPR was considered for evalua-
tion. Similarly, days-between-ﬁlls adherence rate and reﬁll com-
pliance rate (RCR) yield the same adherence values, and hence,
only RCR was considered for evaluation. Thus, in our study, we
compared eight unique measures that have been used to measure
adherence using administrative prescription claims data.
The patients were assumed to be 100% adherent to their
schizophrenia medications during hospitalization admissions in
the 1-year index period. Hence, we subtracted the corresponding
number of days a patient was hospitalized during the index
period from the denominator for all the eight adherence mea-
sures. To check if there was variation in the results, we conducted
a sensitivity analysis where we calculated adherence rates
without adjusting for the time patient was hospitalized in the
1-year, post-index period.
Dependent Variable
Hospitalization in the “postindex period” was deﬁned as any
inpatient admission regardless of the primary diagnosis. Mental
health-related inpatient admissions were deﬁned as any inpatient
admission with a primary diagnosis with the following ICD-
9-CM codes: 295.xx, 296.2x, 296.3x, 296.9x, 300.4x, 309.0x,
311.xx, 300.0x, 300.2x, 300.3x, 306.9x, 308.xx, 309.2x,
309.4x, 309.9x, 297.xx, 298.xx, 299.xx, 300.1x, 302.8x,
307.9x, 290.xx, 291.2x, 310.9x, 331.0. These ICD-9-CM diag-
nosis codes were adapted from a previously published study by
Weiden et al. [6].
Other Covariates
Demographics. Age (calculated based on the date of birth and
the index date), gender, race (whites, blacks, and others) were
based on the Medicaid recipient summary ﬁle.
Previous hospitalization. A marker variable “previous hospital-
ization” was created and deﬁned as any inpatient stay by the
patient during the “index period.”
Comorbidity assessment. A measure of comorbidity was based
on the Chronic Illness and Disability Payment System developed
speciﬁcally for Medicaid programs [21]. Inpatient and outpatient
claims during the index period were used in calculating comor-
bidity scores for the patients.
Prior Cost
Prior cost which included inpatient and outpatient nondrug costs
was computed by summing the cost for each patient in the 1-year
index period.
Admission to rehabilitation center during the index period:
covariate indicating patients admitted to rehabilitation center
during the index period.
Analysis
To determine if the adherence measures are statistically different
from each other, Tukey’s and Bonferroni’s multiple comparisons
tests were used. To access the association between the adherence
measures and hospitalization, we estimated Spearman’s correla-
tion coefﬁcients and logistic regression models for each of the
eight adherence measures. Reduced models including only
the adherence measures and multivariable models including all
the covariates were estimated. Second, we inspected odds ratios
(ORs) and conﬁdence intervals (CIs) to check if the adherence
measure was of the right direction (i.e., as adherence rates
increased, hospitalization rates decreased). We used C-statistics
to select adherence measure that explains the most variability in
hospitalization rates. The C-statistic is deﬁned as the area under
receiver operating characteristic curve [22], and the model with
the highest C-statistic was considered to be the most predictive of
hospitalization. C-statistics for the eight adherence measures
were estimated using the univariate and multivariable logistic
regression models. Second, we also inspected the ORs to identify
those adherence measures most strongly associated with hospi-
talization rates.
A sensitivity analysis was conducted excluding patients dually
eligible for Medicare beneﬁts. This was done as a check to guard
against possible hospital claims that might be missing from the
Medicaid ﬁles for these dually eligible recipients. All the statisti-
cal analyses were conducted using SAS 9.1 (SAS Institute Inc.,
Cary, NC, USA) hosted on the server or the Windows platform.
Results
Baseline Characteristics
The baseline characteristics of the schizophrenia cohort are
described in Table 2. The study cohort consisted of 3395 patients
Table 1 Mathematical formulas for the various adherence measures under evaluation
Adherence measure* Formula
Medication possession ratio† Number of days supply in index period/number of days in the study period (365 days)
Medication reﬁll adherence† [Number of days supply in index period/number of days in the study period (365)] ¥ 100
Continuous measure of medication acquisition† Number of days supply/total days to next ﬁll or end of observation period (365 days)
Proportion of days covered (PDC) [Number of days supply in index period/number of days in the study period (365)] ¥ 100 capped at 1
Reﬁll compliance rate† (Number of days supply/last claim date - index date) ¥ 100
Days-between-ﬁlls adherence rate† 1 - [(Last claim date - index date) - total days supply/last claim date - index date] ¥ 100
Compliance ratio Number of days supply in the index period - last days supply/last claim date - index date
Medication possession ratio, modiﬁed [Number of days supply/(last claim date - index date + last days supply)] ¥ 100
Continuous measure of medication gaps Total days of treatment gaps/total days to next ﬁll or end of observation period (365 days)
Continuous multiple interval measure of oversupply Total days of treatment gaps (+) or surplus (-)/total days to next ﬁll or end of observation period
(365 days)
Continuous, single interval measure of medication
acquisition
Days supply obtained at the beginning of the interval/days in interval
*Hess et al. Ann Pharmacotherapy 2006.
†Mathematically similar formulas for calculating adherence.
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with mean age of 42.8 years of which 52.5% (n = 1782) were
female, 52.8% (n = 1793) were white, and 39% (n = 1327) were
black. Approximately 47.7% (n = 1619) were also Medicare eli-
gible; 23.2% (n = 788) of the patients had an inpatient admission
during the index period. During the post-index period, 28.8%
(n = 979) had an inpatient admission, and 18.1% (n = 616) had
inpatient admission related to a mental health condition.
Adherence Rates
The adherence rates for the schizophrenia cohort are described in
Table 3. Adherence rates were observed to be slightly higher after
excluding the number of days hospitalized from the denominator
in the adherence calculation. The adherence rates varied between
a low of 0.724 for proportion of days covered (PDC) and a high
of 0.909 for RCR for the adherence measures where higher
values correspond to better adherence. The adherence values
were signiﬁcantly different (P < 0.05) from each other for all
the nongap-based possible pair-wise comparisons except RCR–
continuous, single interval measure of medication acquisition
(CSA), compliance ratio (CR)–medication possession ratio,
modiﬁed (MPRm), and PDC–MPR (data not shown). The values
for the gap measures, continuous measure of medication gaps
(CMG) and continuous multiple interval measure of oversupply
(CMOS), were 0.276 and 0.262, respectively, and values closer to
zero correspond to better adherence. MPR, PDC, CMG, and
CMOS, which use the entire index period in the denominator,
tended to have lower adherence values than RCR, CR, and
MPRm which only consider the period between the ﬁrst and last
prescription in the index period.
All eight adherence measures were found to be signiﬁcantly
correlated with hospitalization rates. The six adherence measures
MPR (-0.107, P  0.001), PDC (-0.113, P  0.001), RCR
(-0.048, P  0.006), CR (-0.07, P  0.001), MPRm (-0.066,
P  0.001), and CSA (-0.040, P  0.021) were negatively cor-
related with any-cause hospitalization. Whereas, the two gap-
based adherence measures CMG (0.113, P  0.001) and CMOS
(0.107, P  0.001), are positively correlated with any-cause
hospitalization.
The OR estimates and C-statistics for the full and reduced
models for each of the eight adherence measures considering
any-cause inpatient admission and mental health-related in-
patient admission are presented in Tables 4 and 5.
All adherence measures other than CSA (OR = 0.941 95%
CI: 0.797–1.113) and RCR (OR = 0.833, 95% CI: 0.678–1.024)
were statistically signiﬁcant predictors of any-cause hospitaliza-
tion in the reduced models. The reduced model OR estimates
varied between 0.417 (PDC) and 0.553 (CR) for the nongap
measures indicating that as the adherence rates increase, the
chances of hospitalization decrease. The two gap-based mea-
sures, CMG and CMOS, had ORs of 2.398 and 2.253, respec-
tively, which also demonstrate that improved adherence
decreases the probability of hospitalization. The reduced models
with PDC and CMG as adherence measures had the highest
univariate C-statistics of 0.571. Mathematically, (PDC and
CMG) and (MPR and CMOS) are the inverse of each other;
hence, numerically similar C-statistics should be observed for
these two pairs of measures. Similarly, CMG and PDC had the
highest C-statistics of 0.687 in the full model; however, MPR and
CMOS had slightly lower C-statistics of 0.686. Adherence
measures PDC (OR = 0.498), MPR (OR = 0.519), CMG (OR =
2.007), and CMOS (OR = 1.927) had ORs farthest from 1.
Similar relationships were observed for the models on mental
health hospitalization where PDC and CMG had the highest
C-statistics in both the reduced and full models.
Sensitivity Analysis
In predicting any-cause andmental health-related hospitalization,
PDC and CMG were found to have the highest C-statistics of
0.584 and 0.579, respectively. Even after adjusting for other cova-
riates, models containing these two measures (PDC and CMG)
had the highest C-statistics of 0.686 and 0.671 in predicting
any-cause and mental health-related hospitalization. Models with
MPR and CMOS remained the second best predictors of any-
cause andmental health-related hospitalization after adjusting for
covariates. The same four measures had ORs farthest from 1.0.
Table 2 Baseline characteristics of schizophrenia cohort (N = 3395)
Mean (N) SD (%)
Age (years) 42.9 13.2
18–30 643 18.9
31–40 977 28.8
41–50 928 27.3
51–64 637 18.8
65 and above 210 6.2
Sex
Female 1782 52.5
Male 1613 47.5
Race
White 1793 52.8
Black 1327 39.1
Other/unknown 275 8.1
Medicare eligible 1619 47.7
Comorbidity score 2.1 1.2
Index period hospitalization 788 23.2
Post-index period hospitalization
Any-cause hospitalization 979 28.8
Mental health–related hospitalization 616 18.1
Table 3 Adherence rates for the schizophrenia cohort (N = 3395)
Adherence measure
Adherence rates without
accounting for hospitalization days
Adherence rates after
excluding days hospitalized
Mean SD Mean SD
Medication possession ratio 0.733 0.309 0.738 0.310
Proportion of days covered 0.720 0.295 0.724 0.295
Reﬁll compliance rate 0.902 0.384 0.909 0.386
Compliance ratio 0.766 0.287 0.772 0.288
Medication possession ratio, modiﬁed 0.789 0.246 0.794 0.247
Continuous measure of medication gaps (CMG)* 0.280 0.295 0.276 0.295
Continuous multiple interval measure of oversupply (CMOS)* 0.267 0.309 0.262 0.310
Continuous, single interval measure of medication acquisition 0.880 0.444 0.893 0.464
*CMG and CMOS are gap measure; lower values represent better compliance.
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Discussion
With the availability of different adherence measures that can be
computed using claims data, researchers often face a dilemma in
selecting an adherence measure. Our study compared the predic-
tive validity of eight different adherence measures computed
using administrative claims data for any-cause and disease-
related inpatient episodes. To the knowledge of the researchers,
the present study was the ﬁrst of its kind to prospectively validate
adherence calculated using pharmacy claims among schizophre-
nia patients, and provides an empirical basis for selecting adher-
ence measures based on administrative claims.
All but three of all the possible adherence pair-wise compari-
sons yielded statistically different adherence values than each
other, and there is a 25% difference between the most conserva-
tive measure, PDC = 0.720, and the most optimistic, RCR =
0.902, so the selection of an adherence metric can yield fairly
meaningful differences. All the adherence measures (except RCR
and CSA) were found to be signiﬁcant predictors of inpatient
admission even after adjusting for covariates such as demo-
graphic factors, prior hospitalization, comorbidity, and prior
cost. Among the eight adherence measures, PDC and CMG had
the highest C-statistics and OR farthest from 1, and were the best
predictors of future hospitalization (any cause and mental health
related). MPR and CMOS had very similar C-statistics and were
the two second best predictors of any-cause and mental health-
related hospitalization. Because the formula employed in calcu-
lating PDC is similar to that of MPR, the only difference being
that for PDC the adherence is capped at 1; these ﬁndings are
expected. Our ﬁndings suggest that oversupply or drug stockpil-
ing has a minor impact on hospitalization. These ﬁndings were
robust as PDC remained the best predictor after excluding
patients eligible for Medicare beneﬁts. Researchers can select
between PDC, MPR, CMG, and CMOS in estimating adherence
as the differences in discriminatory power among these four
adherence measures remain relatively small. Nevertheless, we
recommend using MPR or PDC for a couple of reasons. Both
MPR and PDC have formulas in which better compliance corre-
sponds to higher values, thus these two may be preferred because
they provide more intuitive values. Moreover, in our previous
research, we found MPR and PDC to be most predictive of
hospitalizations among diabetes patients [23]. Researchers
should, however, consider MPR as their primary choice in cal-
culating adherence as it has been widely used in many pharmacy
claims-based studies.
In our study, we found that adherence measures using the
entire study period (365 days) as the denominators (MPR, PDC,
CMG, and CMOS) were better predictors of hospitalization
(univariate C-statistic range: 0.567–0.571) as compared to the
adherence measures that only considered the period between ﬁrst
and last reﬁll (RCR, CR, MPRm: univariate C-statistic range:
0.525–0.549). The primary reason for this might be because of
the fact that if we only consider the period between ﬁrst and last
reﬁlls, then it does not account for early discontinuation and
would overestimate adherence for persons that completely
stop taking their medications. Consider a hypothetical scenario
wherein a person ﬁlls three consecutive prescriptions of each
30-day supply and has a 90-day period between the ﬁrst and last
reﬁlls, then the RCR value will be 1.0 (RCR = 90/90), indicating
perfect adherence. The MPR or PDC value for the same person
would be 0.25 (MPR = 90/365). For patients with chronic con-
ditions such as schizophrenia, it is important for these adherence
Table 4 Comparison of odds ratios (ORs), full model, and reduced model* (any-cause hospitalization)
Adherence measure
Full multivariate model Reduced univariate model
OR 95% Wald CI
Pr >
chi-square
C-
statistics OR 95% Wald CI
Pr >
chi-square
C-
statistics
Medication possession ratio 0.519 0.398 0.677 <0.001 0.686 0.444 0.350 0.562 <0.001 0.568
Proportion of days covered 0.498 0.377 0.659 <0.001 0.687 0.417 0.326 0.534 <0.001 0.571
Reﬁll compliance rate 0.911 0.738 1.124 0.383 0.677 0.833 0.678 1.024 0.083 0.530
Compliance ratio 0.653 0.492 0.868 0.003 0.681 0.553 0.427 0.717 <0.001 0.544
Medication possession ratio, modiﬁed 0.617 0.445 0.856 0.004 0.681 0.508 0.378 0.683 <0.001 0.542
Continuous measure of medication gaps (CMG)† 2.007 1.518 2.653 <0.001 0.687 2.398 1.873 3.071 <0.001 0.571
Continuous multiple interval measure of oversupply (CMOS)† 1.927 1.478 2.513 <0.001 0.686 2.253 1.778 2.854 <0.001 0.568
Continuous, single interval measure of medication acquisition 0.897 0.756 1.064 0.212 0.677 0.941 0.797 1.113 0.479 0.525
*Full multivariate model includes covariates—adherence measure, comorbidity score, age, gender, race, prior hospitalization, and prior cost. Reduced univariate model includes only the
adherence measure.
†CMG and CMOS are gap measure; lower values represent better compliance.
Table 5 Comparison of odds ratios (ORs), and full multivariate and reduced univariate model* (mental health hospitalization)
Adherence measure
Full multivariate model* Reduced univariate model
OR 95% Wald CI
Pr >
chi-square
C-
statistics OR 95% Wald CI
Pr >
chi-square
C-
statistics
Medication possession ratio 0.544 0.402 0.736 <0.001 0.665 0.456 0.347 0.600 <0.001 0.567
Proportion of days covered 0.522 0.380 0.717 <0.001 0.666 0.430 0.323 0.572 <0.001 0.571
Reﬁll compliance rate 0.789 0.611 1.017 0.068 0.657 0.711 0.548 0.923 0.011 0.536
Compliance ratio 0.622 0.451 0.858 0.004 0.660 0.522 0.387 0.706 <0.001 0.549
Medication possession ratio, modiﬁed 0.594 0.411 0.859 0.006 0.660 0.484 0.344 0.681 <0.001 0.547
Continuous measure of medication gaps (CMG)† 1.916 1.396 2.632 <0.001 0.666 2.328 1.749 3.099 <0.001 0.571
Continuous multiple interval measure of oversupply (CMOS)† 1.838 1.359 2.486 <0.001 0.665 2.191 1.665 2.883 <0.001 0.567
Continuous, single interval measure of medication acquisition 0.919 0.758 1.115 0.394 0.655 0.957 0.787 1.165 0.663 0.528
*Full multivariate model includes covariates—adherence measure, comorbidity score, age, gender, race, prior hospitalization, and prior cost. Reduced univariate model includes only the
adherence measure.
†CMG and CMOS are gap measure; lower values represent better compliance.
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measures to account for early discontinuations, and our data
support this fact. This study also afﬁrms the importance of
medication adherence in preventing future hospital utilization
[3,5,8,24]. It should also be noted that MPR and PDC were not
statistically different from each other and yielded similar results
which reﬂect the same manner in which these are calculated for
all values less than 1.0.
Certain limitations of this study need to be acknowledged. We
calculated medication adherence using claims data, and thus
the actual consumption of the medication was not estimated
although medication possession is imperative for its consump-
tion. We measured medication adherence in terms of adherence
to monotherapy within a class of drugs prescribed for treating
schizophrenia, but we allowed for patients taking different
strengths of the same drug simultaneously and for switches
between antipsychotics. Focusing on persons taking one antipsy-
chotic at a time limits the generalizability, and the ﬁndings may
not be applicable to patients on more than one concomitant
therapy, which may be presumed to have greater disease severity
and/or lack perceived efﬁcacy. Unfortunately, the adherence mea-
sures we investigated do not have standardized methods for
incorporating multiple concurrent medication use in the calcula-
tions, and we believe that this is an important next step in
advancing adherence measures to handle these complex situa-
tions. Depending on the scope of studies, some analyses consider
medication switches as new therapy starts. Our analysis adopted
the perspective of measuring adherence to antipsychotics in
general, but not to any one particular antipsychotic and ignored
medication switches within the antipsychotic class. This perspec-
tive will yield different adherence values than those that focus on
adherence to a particular antipsychotic, although the relationship
between the adherence values and subsequent hospitalizations
may not be greatly different. Additionally, our study design
allowed for patients taking different strengths of the same drug
simultaneously, thus, adherence rates may be overestimated in
such patients. Several other factors, such as severity of the illness,
side effects, occupational status, education level, patient support
system, and side effects may affect medication adherence as well
as hospitalization, were not available in the data set and were not
included in the multivariable models, and if included, these addi-
tional variables may alter the adjusted relationships we report.
Lastly, the C-statistics reported in the univariate models were
low; none of the adherence measures alone had a C-statistic
>0.60, which indicates that adherence by itself, although statis-
tically signiﬁcant, is a relatively modest factor inﬂuencing subse-
quent hospitalization. The full models which included prior
hospitalization, comorbidity burden, and patient demographics
in addition to the adherence measures had higher C-statistics
greater than 0.60, but less than 0.70 which indicate that subse-
quent hospitalization can only be modestly predicted given the
conﬁnes of an administrative data source.
In our study, we initially considered two outcome measures,
hospitalization and total nonpharmacy costs for discriminating
between adherence measures based on past empirical evidence
which has consistently demonstrated a relationship between
adherence and these two outcome measures. After our initial
analysis, we found a positive correlation between the adherence
measures and nonpharmacy costs, indicating that an increase in
adherence was associated with increased costs which is in con-
trast to several studies that have found a negative correlation
indicating that lower adherence was associated with increased
health-care expenditures and utilization [3–6,8,25]. The positive
correlation observed in our data may be because of the fact that
approximately 83% of our study sample was in a rehabilitation
center during the index or the postindex period. These rehabili-
tation centers are expensive and monitor adherence which may
drive up adherence resulting in the positive association between
nonpharmacy costs and adherence we observed. Given the likely
endogeneity between cost and adherence in these rehabilitation
centers and the fact that a very high percentage of our sample
accessed these centers, we chose to not use nonpharmacy cost to
discriminate between these different adherence measures. Lastly,
there are other possible dependent measures such as medication
augmentation or switching that may also have the potential to
discriminate between adherence measures, and we encourage
future research in this area.
In our literature review, we came across nonconsistent
nomenclature used for adherence measures where the same term
might have two different mathematical expressions or deﬁnitions
[18]. For example, adherence measures such as continuous mul-
tiple reﬁll interval measure of medication availability (CMA),
medication-total (MED_TOT), are used synonymously with
MPR [18,19,26,27]. Conversely, we also found that different
terms have the same mathematical expression or deﬁnition
[18,28–33]. Because the objective of our study was to validate
the measures, we adopted the nomenclature and formulas used
by Hess et al. in their study [19]. Secondly, our adherence deﬁ-
nitions were based on the most recent published literature [19] at
the time this study was undertaken, and we acknowledge that
newer adherence deﬁnitions may have evolved. One of the adher-
ence measures, PDC, has been deﬁned differently than deﬁned in
this report, and the alternative deﬁnition for PDC should be
considered [34]. The PDC deﬁnition in our paper may alterna-
tively be described as a “capped” MPR or MPR modiﬁed
measure. Because our study provides the precise formulas for the
adherence measures, we suggest that future researchers and prac-
titioners consider using these deﬁnitions, except for PDC, and
names when describing adherence measures in the future.
Conclusion
Signiﬁcant associations were observed between six different mea-
sures of medication adherence any-cause and disease-speciﬁc
hospitalization rates among patients with schizophrenia. Among
schizophrenia patients not prescribed polypharmacy, we found
that the PDC, MPR, CMOS, and CMG were the best predictors
of any-cause and mental health-related hospitalization as com-
pared to other adherence measures. Overall adherence measures
considering an index period of 365 days as the denominator were
better predictors of subsequent hospitalization as compared to
adherence measures that only considered the period between the
ﬁrst and last reﬁlls. The MPR and PDC provide similar intuitively
appealing adherence values, where better adherence corresponds
to higher values, and had the highest predictive validity for
subsequent hospitalizations. Ideally, persons should explore a
range of possible metrics to measure adherence, but in instances
when only a single adherence calculation is sought, persons
should ﬁrst consider these measures when calculating adherence
from administrative claims data for persons with schizophrenia.
Our recommendations are based on the ability of the adherence
measures to predict one outcome—hospitalization. Additional
studies are warranted to measure the predictive ability of adher-
ence measures on other potential outcomes.
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